Inhibikase Therapeutics, Inc. (IKT) is a Healthcare stock trading at $2.39 (as of 2026-08-21), with a market capitalization of $333.49M. Figures are sourced from first-party U.S. SEC EDGAR filings and market data.
Inhibikase Therapeutics, Inc., a clinical stage pharmaceutical company, develops therapeutics for Parkinson's Disease (PD) and related disorders that arise inside and outside of the brain. The company's product candidates include IkT-148009, a small molecule Abelson tyrosine kinase inhibitor for use in the treatment of PD, as well as gastrointestinal complications that arise as early symptoms of PD, such as swallowing, dysphagia, neurogenic constipation, and multiple system atrophy; and IkT-001Pro, a prodrug of the anti-cancer agent Imatinib that is in preclinical development to minimize gastrointestinal side effects and for the treatment of blood and stomach cancers. It is also involved in developing various research programs for other neurological diseases. The company has research and development collaborations with The Johns Hopkins University, Arizona State University, and Michigan State University, as well as Louisiana State University. Inhibikase Therapeutics, Inc. was founded in 2008 and is headquartered in Atlanta, Georgia.
Inhibikase Therapeutics develops clinical stage treatments for Parkinson's disease and related disorders, and it currently makes money only through Grant Revenue and Rent Revenue (both reported as zero in the latest quarter).
With reported revenue of 0.0B (from Grant Revenue and Rent Revenue), the profit model is structurally tied to advancing clinical programs, where near-term performance is tracked through trial execution metrics such as enrollment and trial site activity for Rizvodetanib and other Phase II programs.
| Grant | $0.0B |
| Rent | $0.0B |
Business quality (Weak): Clinical-stage visibility is high on trial execution metrics, but financial revenue is reported as 0.0B, so near-term fundamentals depend heavily on progress in clinical development rather than current sales.
| Price | $2.39 |
| Market Cap | $333.49M |
| Price / Book | 2.18 |
| FCF Yield | -20.7% |
| Revenue (TTM) | $0.00 |
| Revenue Growth (YoY) | -100.0% |
| EPS Growth (YoY) | -67.5% |
| FCF Growth (YoY) | 5.8% |
| Sector P/E (Healthcare) | 21.7 |
| Industry P/E (Pharmaceutical Products) | 17.2 |
| Top Institutional Holder | Sands Capital Alternatives, LLC ($21.87M) |
| Institutional Holders Tracked | 10 |
| Sector | Healthcare |
| Industry | Pharmaceutical Products |
| CEO | Mark T. Iwicki |
| Employees | 15 |
| Country | US |
| IPO Date | 2020-12-23 |
Data as of 2026-08-21.
Figures sourced from U.S. Securities and Exchange Commission (SEC EDGAR) filings and market data. Not personalized investment advice.